Anastasiya Sviridova

Dr. Anastasiya Sviridova

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MBMarina Kleopatra Boziki
Marina Kleopatra Boziki
EKEvangelia Kesidou
Evangelia Kesidou
Paschalis TheotokisPaschalis Theotokis
Paschalis Theotokis
AMAlexios-Fotios Mentis
Alexios-Fotios Mentis
EKELENI KARAFOULIDOU
ELENI KARAFOULIDOU
NGNikolaos Grigoriadis
Nikolaos Grigoriadis
An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut–brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated.

Verified
Journal Article
Open access
PDF file
MMMikhail Melnikov
Mikhail Melnikov
VRVladimir S. Rogovskii
Vladimir S. Rogovskii
ASAnastasiya Sviridova
Anastasiya Sviridova
ALAnna Lopatina
Anna Lopatina
MPMikhail V. Pashenkov
Mikhail V. Pashenkov
ABAlexey Boyko
Alexey Boyko
Norepinephrine is a neurotransmitter that also has an immunomodulatory effect and is involved in multiple sclerosis (MS) pathogenesis. This study aimed to clarify the role of the β2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-γ (IFN-γ) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or β2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA. Norepinephrine suppressed IL-17 and IFN-γ production by the anti-CD3/anti-CD28-microbead-stimulated CD4+ T cells in both groups. Blockade of the β2-adrenoreceptor with the specific antagonist ICI 118.551 enhanced norepinephrine-mediated IL-17 suppression but decreased its inhibitory effect on IFN-γ production in MS patients. In contrast, the β2-adrenoreceptor agonist formoterol did not influence norepinephrine’s inhibitory effect on cytokine production in both groups. The blockade of the β2-adrenoreceptor, even in the absence of exogenous norepinephrine, suppressed IL-17 production but did not influence IFN-γ production in both groups. Conversely, β2-adrenoreceptor activation by formoterol decreased IFN-γ production and did not affect IL-17 production in both groups. These data illustrate the inhibitory effect of norepinephrine on IL-17 and IFN-γ production by CD4+ T cells in MS. The inhibitory effect of norepinephrine on IFN-γ production by CD4+ T cells in MS could be mediated via β2-adrenoreceptor activation.

1 January 2020 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
ЛКЛ. В. Кривенко
Л. В. Кривенко
ASAnastasiya Sviridova
Anastasiya Sviridova
МММ. В. Мельников
М. В. Мельников
VRV.S. Rogovskii
V.S. Rogovskii
ABA.N. Boyko
A.N. Boyko
MPM.V. Pashenkov
M.V. Pashenkov
Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS). 5 patients with relapsing-remitting MS and five healthy subjects were examined. Levels of IL-6 and IL-1β were measured by ELISA in culture supernatants obtained from lipopolysaccharide stimulated dendritic cells. To assess the effect of fluoxetine on cytokine production, dendritic cells were stimulated in the presence of fluoxetine and antagonists of 5-HT1A-, 5-HT2A-, 5-HT2B-receptors or agonist of 5-HT2B-receptors. Cytokine production by dendritic cells was comparable in both groups. Fluoxetine suppressed IL-6 and IL-1β production in both groups. Blockade of 5-HT2B-receptors with specific antagonist RS 127445 reduced the inhibitory effect of fluoxetine on IL-1β production in both groups and IL-6 production in healthy subjects. In contrast, activation of 5-HT2B-receptors by specific agonist BW 723C86 increased the inhibitory effect of fluoxetine on IL-6 production by dendritic cells in both groups, but did not affect on IL-1β production. These data suggest an anti-inflammatory effect of fluoxetine in MS by modulating pro-inflammatory cytokines production by dendritic cells. This effect could be mediate by activation of 5-HT2B-receptors.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MMMikhail Melnikov
Mikhail Melnikov
ASAnastasiya Sviridova
Anastasiya Sviridova
VRVladimir S. Rogovskii
Vladimir S. Rogovskii
ABAlexey Boyko
Alexey Boyko
MPM.V. Pashenkov
M.V. Pashenkov
Рассеянный склероз (РС) — хроническое демиелинизирующиее и нейродегенеративное заболевание центральной нервной системы (ЦНС) с аутоиммунным механизмом развития. Известно, что наряду с T- и B-лимфоцитами клетки врожденной иммунной системы также играют существенную роль в патогенезе РС. Макрофаги занимают центральное место в функционировании врожденной системы иммунного ответа и в зависимости от фенотипа обладают как про-, так и противовоспалительными свойствами. В ЦНС резидентные макрофаги формируют микроглию, способную презентировать антигены и продуцировать цитокины и в зависимости от активационного статуса участвовать как в развитии аутоиммунного воспаления, так и в поддержании иммунологической толерантности. В коротком сообщении представлены данные об участии макрофагов в патогенезе экспериментального аутоиммунного энцефаломиелита и РС. Обсуждаются современные методы модуляции функций макрофагов с целью терапии РС.

1 January 2019 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
ASAnastasiya Sviridova
Anastasiya Sviridova
OBO. O. Belousova
O. O. Belousova
VRV. S. Rogovskii
V. S. Rogovskii
MPM. V. Pashenkov
M. V. Pashenkov
ABA. N. Boyko
A. N. Boyko
MMM. V. Melnikov
M. V. Melnikov
Medical article медицинская статья

8 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
RZR.R. Zhetishev
R.R. Zhetishev
ALA.V. Lopatina
A.V. Lopatina
ASAnastasiya Sviridova
Anastasiya Sviridova
MMMikhail Melnikov
Mikhail Melnikov
Objective. To systematize data on the role of monocytes in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Material and methods. Forty-six scientific publications (1990—2024) on the role of monocytes in the pathogenesis of EAE and MS were analyzed. Results. Monocytes have been found to play an essential role in both the occurrence and persistence of autoimmune neuroinflammation. They penetrate the central nervous system (CNS) through the blood-brain barrier, produce pro-inflammatory cytokines, differentiate into macrophages/dendritic cells, and activate CD4+ T-cells. The change in both quantitative and functional characteristics of monocytes in MS is described. Conclusion. Monocytes are involved in all stages of the immunopathogenesis of EAE and MS and largely mediate autoimmune demyelination in the CNS. Therefore, they can be considered a potential therapeutic target for MS.